Tianjin Medical University Cancer Institute and Hospital

Tianjin Medical University Cancer Institute and Hospital (Chinese: 天津市肿瘤医院与天津医科大学附属肿瘤医院; pinyin: Tiānjīn shì zhǒngliú yīyuàn yǔ tiānjīn yīkē dàxué fùshǔ zhǒngliú yīyuàn) is a cancer research institute based in China.

History

The hospital was established in 1861 with the name of London Christian Church Hospital. Jin Xianzhai, the well-known oncologist, set up the first tumor ward in the hospital in 1952. In 1972, the hospital became a specialized cancer hospital with 341 beds. In 1977, the Institute of Cancer Research was established with eight departments. The institute is dedicated to cancer research, treatment, and prevention. The institute was established by Professor Jin Xianzhai, a prominent Chinese oncologist, it originated as the Cancer Prevention Research Laboratory within Tianjin People's Hospital. Over the years, it has evolved and expanded its scope, eventually becoming a significant player in the field of oncology.

Since its inception the Tianjin Medical University Cancer Institute and Hospital (TMUCIH) has played a pivotal role in advancing medical expertise in the field of oncology and pathology. Tasked by the Ministry of Health, the institute took the lead in initiating the "Advanced National oncologists and Pathologists Training Course," a significant endeavor aimed at nurturing specialized professionals in the battle against cancer. Tianjin Medical University Cancer Institute and Hospital is one of the largest bases for cancer prevention, treatment, training and research in China. Tianjin Medical University Cancer Institute and Hospital (TMUCIH) strives to provide the best treatment in China to cancer patients and is one of the largest cancer centers in China, with 2319 beds, 46 clinical and diagnostic departments and 13 research departments.

On 13 of July, 2020, TMUCIH signed an agreement on cooperation with the National Cancer Center Hospital in Japan.

Cancer prevention and treatment research center

Tianjin Medical University is constructing the largest cancer prevention, treatment, and research base in Asia. On June 27, 1989 construction of the comprehensive cancer prevention and treatment research center, with a gross floor area of 93,000 square meters, started at Tianjin Medical University Cancer Institute and Hospital. Upon completion, the hospital will have 1,800 beds, be able to serve 500,000 outpatients, and perform over 20,000 surgical operations annually.

In 2017, Oncology was ranked as the National "world class" Academic Development by the Ministry of Education, Ministry of Finance and the National Development and reform commission.

Departments

The hospital has about 1.3 million visits and 32,000 surgeries every year. The cancer institute has 12 departments; Cancer Epidemiology & Biostatistics Laboratory, the Pathology Laboratory, the Biochemistry & Molecular Biology Laboratory, the Cancer Cell Biology Laboratory, the Immuno-Biotechnology Laboratory, the Gastrointestinal Tumor Biology Laboratory, the Pharmacology Laboratory, the Public Laboratory, the Tumor Molecular Diagnostic Center, the Tissue Bank, the Library and the Editorial Department. - Throughout its history, the Institute has been under the leadership of distinguished figures in the field. Successive directors include Jin Xianzhai, Zhou Yanchang, Zhang Tianze, and Jin Jiarui. Currently, the Institute is led by Academician Hao Xishan, who serves as the director. Assisting in this role are three deputy directors: Professor Ying Guoguang, Professor Niu Ruifang, and Professor Li Hui.

Quick Facts

The Main Campus of the Hospital has a land space of 69,000m² and building area of 175,052m². As of 2018, there have been 1,224,629 outpatient visits and 103,123 in-patient visits. As of 2019, there are 2,319 beds and a staff of 2,968 employees. There are in total 3 locations of the Tianjin Medical Institute including the main campus, Airport Free Trade Zone Hospital, and the Binhai Hospital.

Future Breakthroughs

The hospital will become the largest cancer prevention, treatment and research base in Asia, incorporating fundamental oncological research, clinical treatment and high-end training. Their Motto is "To provide patients with the uttermost integrity and state of the art medicine. To improve our profession with integrity and innovations".

The center plans to make a breakthrough in integrating clinical treatment and scientific research; seven clinical research centers will be constructed, with a view to realizing a "seamless interconnection" between clinical treatment and scientific research.